Intestinal Flora Differences Between Colorectal Cancer Patients and Healthy Individuals

March 13, 2025 updated by: Hansung University

Intestinal Flora Differences Between Colorectal Cancer Patients and Healthy Individuals: A Case-Control Study

This observational case-control study aims to compare the composition of intestinal microbiota between colorectal cancer (CRC) patients and healthy individuals. Fecal samples from 36 CRC patients and 25 healthy controls were analyzed for bacterial abundance. Results indicate significant differences in beneficial, neutral, and harmful bacterial populations between groups, with CRC patients showing reduced beneficial flora (e.g., Lactobacillus) and increased harmful/neutral flora (e.g., Staphylococcus). Further stratification by cancer stage (I-III) revealed progressive dysbiosis with disease progression.

Study Overview

Detailed Description

This observational case-control study investigates the compositional differences in intestinal microbiota between individuals diagnosed with colorectal cancer (CRC) and healthy controls. The study enrolled 36 CRC patients confirmed by histopathology and 25 age- and gender-matched healthy volunteers without gastrointestinal diseases or antibiotic/probiotic use within the preceding three months. Fecal samples were collected from CRC patients at the time of diagnosis and from healthy participants during routine health screenings. Utilizing 16S rRNA sequencing or quantitative PCR, the relative abundance of specific bacterial taxa (e.g., Lactobacillus, Bifidobacterium, Staphylococcus) was quantified to assess dysbiosis patterns. Additionally, the analysis stratified CRC patients by clinical stage (I-III) to explore progressive shifts in microbial communities with disease advancement. The findings aim to elucidate the role of gut microbiota in CRC pathogenesis and provide insights into potential microbiome-based diagnostic or therapeutic strategies.

Study Type

Observational

Enrollment (Actual)

61

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Guangdong
      • Zhanjiang, Guangdong, China, 524002
        • Central Hospital of Guangdong Provincial Nongken

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Retrospective case-control study of 36 CRC patients (stages I-III, diagnosed 2022-2023) and 25 healthy controls from Central Hospital, Zhanjiang, China. CRC group: pre-treatment fecal samples, TNM staging. Control group: age/gender-matched, no GI diseases, normal colonoscopy/fecal tests. Exclusions: antibiotic/probiotic use (past 3 months), inflammatory bowel disease, incomplete records.

Description

Inclusion Criteria:

  • Adults (≥18 years) with histopathologically confirmed colorectal cancer (CRC group)
  • Archived fecal sample available from time of CRC diagnosis (prior to treatment)
  • Complete clinical records including TNM staging (I-III) for CRC patients
  • Age- and gender-matched adults without CRC history (control group)
  • Archived fecal sample available from routine health check-ups (control group)

Exclusion Criteria:

  • Recent antibiotic or probiotic use (within 3 months)
  • History of inflammatory bowel disease
  • Incomplete medical records
  • For controls: history of colorectal cancer, polyps, or chronic gastrointestinal diseases
  • For controls: abnormal colonoscopy or fecal occult blood test within the past year

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
CRC Patients

Participants: 36 individuals with histopathologically confirmed colorectal cancer.

Data Source: Archived fecal samples and medical records from patients diagnosed between January 2022 and October 2023.

Inclusion Criteria:

Adults (≥18 years). Newly diagnosed CRC without prior chemotherapy/radiotherapy. Availability of fecal samples collected at diagnosis.

Exclusion Criteria:

Antibiotic/probiotic use within 3 months before sample collection. Concurrent gastrointestinal infections or inflammatory bowel disease. Subgroups: Stratified by clinical stage (I, II, III) based on TNM classification from medical records.

Retrospective analysis of gut microbiota in CRC patients vs. healthy controls. No interventions were administered; data were collected from archived samples and medical records.
Healthy Controls

Participants: 25 age- and gender-matched individuals without gastrointestinal diseases or cancer history.

Data Source: Archived fecal samples and health screening records from routine check-ups during the same period.

Inclusion Criteria:

Adults (≥18 years). No history of colorectal polyps, cancer, or chronic gastrointestinal disorders. Normal colonoscopy or fecal occult blood test results.

Exclusion Criteria:

Antibiotic/probiotic use within 3 months before sample collection. Recent acute gastrointestinal symptoms (e.g., diarrhea, constipation).

Retrospective analysis of gut microbiota in CRC patients vs. healthy controls. No interventions were administered; data were collected from archived samples and medical records.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of Mean Relative Abundance of Intestinal Bacterial Genera between CRC Patients and Healthy Controls
Time Frame: Retrospective analysis of fecal samples collected between January 2021 and March 2025
The primary metric is the mean relative abundance of specific intestinal bacterial genera (e.g., Lactobacillus, Bifidobacterium, Staphylococcus). Quantitative comparison will be performed between CRC patients and healthy controls using data obtained from fecal samples via 16S rRNA sequencing or qPCR. This is a retrospective analysis of samples collected between January 2021 and March 2025.
Retrospective analysis of fecal samples collected between January 2021 and March 2025

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2021

Primary Completion (Actual)

March 1, 2025

Study Completion (Actual)

March 1, 2025

Study Registration Dates

First Submitted

March 10, 2025

First Submitted That Met QC Criteria

March 10, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 13, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared publicly due to restrictions imposed by the hospital ethics committee and Chinese data privacy laws.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe